Glenmark Pharma receives USFDA nod for Sevelamer Hydrochloride tablets
- Country:
- India
Glenmark Pharmaceuticals Monday said it has received final approval from the US health regulator for Sevelamer Hydrochloride tablets, used to control serum phosphorus in patients with chronic kidney disease on dialysis. The approved product is a generic version of Genzyme Corporation's Renagel tablets.
"Glenmark Pharmaceuticals Inc, USA (Glenmark) has been granted final approval by the United States Food and Drug Administration (USFDA) for Sevelamer Hydrochloride tablets in the strengths of 400 mg and 800 mg," the company said in a BSE filing. For the 12 months to December 2018, Renagel tablets market achieved annual sales of approximately USD 102.1 million, Glenmark said, citing IQVIA sales data.
The company's current portfolio consists of 149 products authorised for distribution at the US marketplace and 53 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA. The company's stock was trading at Rs 604.25, down 1.66 per cent, on BSE.
(With inputs from agencies.)
- READ MORE ON:
- Graphics tablet
- Tablet computer
- Emerald Tablet
- Step by Step
- Alzheimer's disease
- Old age
- Food and Drug Administration
- Better Business Bureau
- Attorney general
- Dairy product
- Hairstyling product
- Heritage USA
- Miss USA Pageant
- Virgin Mobile USA
- Glenmark Pharmaceuticals
- tablets
- Sevelamer Hydrochloride
- patients
- product
- United States Food and Drug Administration
ALSO READ
Margot Robbie's production company LuckyChap brings new film project based on classic board game Monopoly
Italian fashion designer Roberto Cavalli has died at age 83, his company says on Instagram, reports AP.
Italian fashion designer Roberto Cavalli has died at age 83, his company says
Italian designer Cavalli passes away, company says
India biz helps TCS post 9 pc jump in Q4 net profit; company says FY25 to be better
Google News